138 related articles for article (PubMed ID: 20596746)
21. Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
Thuss-Patience PC; Kretzschmar A; Repp M; Kingreen D; Hennesser D; Micheel S; Pink D; Scholz C; Dörken B; Reichardt P
J Clin Oncol; 2005 Jan; 23(3):494-501. PubMed ID: 15659494
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of first-line systemic chemotherapy with epirubicin, cisplatin plus 5-fluorouracil and docetaxel, cisplatin plus 5-fluorouracil regimens in locally advanced inoperable or metastatic gastric or gastroesophageal junction adenocarcinoma: A prospective phase II study from South India.
Babu KG; Chaudhuri T; Lakshmaiah KC; Dasappa L; Jacob LA; Babu M; Rudresha AH; Lokesh KN; Rajeev LK
Indian J Cancer; 2017; 54(1):47-51. PubMed ID: 29199662
[TBL] [Abstract][Full Text] [Related]
23. A phase II study of combination therapy with 5'-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci.
Koizumi W; Kurihara M; Sasai T; Yoshida S; Morise K; Imamura A; Akazawa S; Betsuyaku T; Ohkubo S; Takahashi H
Cancer; 1993 Aug; 72(3):658-62. PubMed ID: 8334621
[TBL] [Abstract][Full Text] [Related]
24. Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
Weinreich J; Schott TC; Königsrainer I; Küper M; Königsrainer A; Schott H
Anticancer Res; 2012 Oct; 32(10):4299-305. PubMed ID: 23060550
[TBL] [Abstract][Full Text] [Related]
25. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.
Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A
Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of branched and conformationally restricted analogs of the anticancer compounds 3'-C-ethynyluridine (EUrd) and 3'-C-ethynylcytidine (ECyd).
Hrdlicka PJ; Andersen NK; Jepsen JS; Hansen FG; Haselmann KF; Nielsen C; Wengel J
Bioorg Med Chem; 2005 Apr; 13(7):2597-621. PubMed ID: 15755661
[TBL] [Abstract][Full Text] [Related]
27. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting.
Kilickap S; Yalcin S; Ates O; Tekuzman G
Hepatogastroenterology; 2011; 58(105):208-12. PubMed ID: 21510316
[TBL] [Abstract][Full Text] [Related]
28. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
Roth AD; Fazio N; Stupp R; Falk S; Bernhard J; Saletti P; Köberle D; Borner MM; Rufibach K; Maibach R; Wernli M; Leslie M; Glynne-Jones R; Widmer L; Seymour M; de Braud F;
J Clin Oncol; 2007 Aug; 25(22):3217-23. PubMed ID: 17664469
[TBL] [Abstract][Full Text] [Related]
29. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.
Al-Batran SE; Homann N; Pauligk C; Goetze TO; Meiler J; Kasper S; Kopp HG; Mayer F; Haag GM; Luley K; Lindig U; Schmiegel W; Pohl M; Stoehlmacher J; Folprecht G; Probst S; Prasnikar N; Fischbach W; Mahlberg R; Trojan J; Koenigsmann M; Martens UM; Thuss-Patience P; Egger M; Block A; Heinemann V; Illerhaus G; Moehler M; Schenk M; Kullmann F; Behringer DM; Heike M; Pink D; Teschendorf C; Löhr C; Bernhard H; Schuch G; Rethwisch V; von Weikersthal LF; Hartmann JT; Kneba M; Daum S; Schulmann K; Weniger J; Belle S; Gaiser T; Oduncu FS; Güntner M; Hozaeel W; Reichart A; Jäger E; Kraus T; Mönig S; Bechstein WO; Schuler M; Schmalenberg H; Hofheinz RD;
Lancet; 2019 May; 393(10184):1948-1957. PubMed ID: 30982686
[TBL] [Abstract][Full Text] [Related]
30. Molecular mechanisms of apoptosis induced by 3'-ethynylcytidine.
Wataya Y; Naito T; Sato A; Hiramoto A; Kitade Y; Sasaki T; Matsuda A; Fukushima M; Kim HS
Nucleic Acids Symp Ser (Oxf); 2009; (53):291-2. PubMed ID: 19749375
[TBL] [Abstract][Full Text] [Related]
31. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
Suttie SA; Park KG; Smith TA
Br J Cancer; 2007 Oct; 97(7):902-9. PubMed ID: 17848947
[TBL] [Abstract][Full Text] [Related]
32. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)-cytosine, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity.
Hattori H; Tanaka M; Fukushima M; Sasaki T; Matsuda A
J Med Chem; 1996 Dec; 39(25):5005-11. PubMed ID: 8960561
[TBL] [Abstract][Full Text] [Related]
33. An RNA-directed nucleoside anti-metabolite, 1-(3-C-ethynyl-beta-d-ribo-pentofuranosyl)cytosine (ECyd), elicits antitumor effect via TP53-induced Glycolysis and Apoptosis Regulator (TIGAR) downregulation.
Lui VW; Lau CP; Cheung CS; Ho K; Ng MH; Cheng SH; Hong B; Tsao SW; Tsang CM; Lei KI; Yamasaki Y; Mita A; Chan AT
Biochem Pharmacol; 2010 Jun; 79(12):1772-80. PubMed ID: 20219441
[TBL] [Abstract][Full Text] [Related]
34. Induction of apoptosis in cervical cancer cells by the duplex drug 5-FdU-ECyd, coupling 2'-deoxy-5-fluorouridine and 3'-C-ethinylcytidine.
Schott S; Brüning A
Gynecol Oncol; 2014 Nov; 135(2):342-8. PubMed ID: 25178996
[TBL] [Abstract][Full Text] [Related]
35. PK-PD modeling of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and the enhanced antitumor effect of its phospholipid derivatives in long-circulating liposomes.
Takada A; Kamiya H; Shuto S; Matsuda A; Harashima H
Int J Pharm; 2009 Jul; 377(1-2):52-9. PubMed ID: 19426792
[TBL] [Abstract][Full Text] [Related]
36. [Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
Seitz JF; Duffaud F; Dahan L; Ries P; Ville E; Laugier R
Cancer Radiother; 2001 Nov; 5 Suppl 1():107s-112s. PubMed ID: 11797269
[TBL] [Abstract][Full Text] [Related]
37. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
[TBL] [Abstract][Full Text] [Related]
38. [A case of 10-year survival after combination chemotherapy of 5'-deoxy-5-fluorouridine and cisplatin and adjuvant surgery for gastric cancer with liver metastasis].
Ichikawa J; Koizumi W; Tanabe S; Takeuchi H; Nagaba S; Higuchi K; Sasaki T; Tahara K; Murakami S; Kitamura T; Nakai H; Saigenji K
Gan To Kagaku Ryoho; 2004 Feb; 31(2):255-8. PubMed ID: 14997763
[TBL] [Abstract][Full Text] [Related]
39. Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Thuss-Patience PC; Kretzschmar A; Krenn V; Dörken B; Reichardt P
Onkologie; 2003 Feb; 26(1):63-5. PubMed ID: 12624520
[TBL] [Abstract][Full Text] [Related]
40. Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
Unek IT; Unek T; Oztop I; Akman T; Atilla K; Ellidokuz H; Bora S; Sarioglu S; Yilmaz U
Chemotherapy; 2012; 58(3):233-40. PubMed ID: 22832016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
